INCLINE-101 INCLINE-101: A Phase 1/2, open label, dose escalation and expansion study of TAC-001 in patients with select advanced or metastatic solid tumors

NCT05399654

INCLINE-101: A Phase 1/2, open label, dose escalation and expansion study of TAC-001 in patients with select advanced or metastatic solid tumors

Principal Investigator

Guru Sonpavde

Sponsor

Tallac Therapeutics, Inc.

The purpose of this study is to test the safety of an investigational (experimental) drug, TAC-001, to see what affects it has on patients with cancer. TAC-001 is considered investigational in this study because it has not been approved by the United States Food and Drug Administration (U.S. FDA), the health authority that gives approval for new medicines to be prescribed in the United States.

This study is currently enrolling.